IBD patients get high protection from COVID-19 mRNA vaccine even when using immunomodulator therapy

People with IBD can be reassured by findings from Israel’s highly vaccinated population that Pfizer’s COVID-19 vaccine has “excellent” and “comparable” effectiveness in IBD patients compared to the general population. Findings published in Gastroenterology are based on an analysis of vaccine efficacy in 12,231 IBD patients and 36,254 matched patients who received the Pfizer Cominarty ...

Already a member?

Login to keep reading.

© 2021 the limbic